FDA Brief

Warning letters Drugs

FDA warning letter to

Indoco Remedies Limited

High riskIssued Dec 16, 2024Posted Jan 7, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Indoco Remedies over manufacturing quality failures at its Goa plant, including unreliable microbial testing and aseptic processing deficiencies.

What happened

FDA inspected Indoco Remedies' drug manufacturing facility in Vasco Da Gama, Goa, India, from July 16 to 26, 2024. FDA found unreliable microbiological testing, inadequate airflow studies and unsuitable aseptic equipment conditions, plus deficient complaint investigations and unreviewed chromatography audit-trail messages. FDA said similar violations were cited in a February 2023 inspection.

What FDA found

  1. The company lacked adequate controls to ensure microbiological test results were reliable, with particles on plates and filters and inconsistent media plate contact.

    21 CFR 211.160(a)
  2. The company did not establish and follow adequate written procedures to prevent microbial contamination of sterile drugs, and airflow smoke studies were inadequate and repeated.

    21 CFR 211.113(b)
  3. The company did not maintain equipment used to control aseptic conditions; FDA observed rough metal surfaces, protruding items, and exposed wires in ISO 5 areas.

    21 CFR 211.42(c)(10)(vi)
  4. The company's investigations into complaints about blocked dispensing tips and missing or empty units were not scientifically sound.

    21 CFR 211.192
  5. The quality unit did not ensure review of chromatography software warning and error messages or all audit-trail data.

    21 CFR 211.22(a) and 211.22(d)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective actions and a schedule for any delays. FDA also recommends engaging a qualified Current Good Manufacturing Practice (CGMP) consultant.

Who should pay attention

  • companies that rely on Indoco as a contract manufacturer
  • brands and distributors selling Indoco-made finished drug products
  • quality teams overseeing supplier qualification and complaint investigations

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk